摘要:
Verfahren zur Herstellung von N-(2-Sulfatoethyl)piperazin-sulfat, indem man N-(2-Hydroxyethyl)piperazin in einer Mischung aus hoch oder höher prozentiger Schwefelsäure und Oleum oder Chlorsulfonsäure bei Temperaturen von etwa 80°C bei etwa 250°C umsetzt, das angefallene Sulfiergemisch in einen mit Wasser mischbaren aliphatischen Alkohol einträgt und das gebildete N-(2-Sulfatoethyl)piperazin-sulfat isoliert.
(R¹ C₁-C₄-Alkyl, C₁-C₄-Halogenalkyl, C₁-C₄-Alkoxy, Halogen, Cyano, Nitro, C₂-C₄-Alkenyl, C₂-C₄-Alkinyl; X Methylen, Ethylen, Vinylen; R², R³ C₁-C₄-Alkyl, C₃-C₆-Cycloalkyl oder gemeinsam Tetra- oder Pentamethylen; R⁴ C₁-C₄-Alkyl, Methoxy; n 2, 3 oder 4), sowie deren physiologisch verträgliche Säureadditionssalze, ihre Verwendung auf dem Arzneimittelgebiet, daraus hergestellte Arzneimittel und deren Verwendung zur Behandlung von Herzrhythmusstörungen und/oder zur Herzfrequenzsenkung.
摘要翻译:式的取代的N-酰苯胺I (R:C1-C4烷基,C1-C4卤代烷基,C1-C4烷氧基,卤素,氰基,硝基,C2-C4烯基,C2-C4炔基; X:亚甲基 乙烯,亚乙烯基; R 2,R 3:C1-C4烷基,C3-C6环烷基或一起为四 - 或五亚甲基; R <4>:C1-C4烷基,甲氧基,N:2,3或4),和 其生理学上可接受的酸加成盐,其在药学领域的使用,制备药物组合物,由其及其心律不齐和/或心脏速率降低的治疗中的用途。
摘要:
A class of ethanoanthracene derivatives is described having use in treatment of CNS disorders such as psychotic, convulsive and dystonic disorders. Compounds of particular interest are those of the formula wherein each of R 5 and R 6 is independently selected from hydrido, loweralkyl, benzyl and phenyl; wherein each of R 7 through R 11 - is independently selected from hydrido, loweralkyl, hydroxy, benzyl, phenyl, loweralkoxy, phenoxy, benzyloxy, halo and haloloweralkyl; wherein R 12 may be selected from hydrido, loweralkyl, cycloalkyl of five or six carbon atoms, cycloalkylalkyl of six or seven carbon atoms, phenyl, hydroxyloweralkyl, and heteroaryl selected from saturated or fully unsaturated heterocyclic rings containing five to seven ring members of which one or two ring members are nitrogen atom; wherein each Y is independently one or more groups selected from hydrido, hydroxy, loweralkyl, benzyl, phenyl, loweralkoxy, phenoxy, haloloweralkyl, halo, and loweralkanoyl; and wherein each of R 13 through R 20 is independently selected from hydrido, lower alkyl, benzyl, phenyl and halo; wherein R 12 together with one of R 13 , R 14 , R 19 or R 20 may form a fused heterocyclic ring containing five or six ring members; or a pharmaceutically-acceptable salt thereof.
摘要:
Die vorliegende Erfindung betrifft Cyclophane der allgemeinen Formel
in der X₁, X₂, A, R und R₁ bis R₄ wie im Anspruch 1 definiert sind, deren Enantiomere, deren Diastereomere, deren Additionssalze, insbesondere für die pharmazeutische Anwendung deren physiologisch verträgliche Additionssalze, welche wertvolle Eigenschaften aufweisen, insbesondere wertvolle pharmakologische Eigenschaften wie eine blutdrucksenkende und coronardilatatierende sowie eine milde herzfrequenzsenkende Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung.
摘要:
Disclosed are amines endowed with fungicidal activity, said compounds having the general formula (I):
wherein:
R₁ and R₂, among others, represent hydrogen, (C₁-C₆)-alkyl groups and groups Ar-B in which Ar is a (C₆-C₁₀)-(halo)-aryl group and B is an (alkyl)-(C₁-C₄)-alkylene group, R₃ and R₅ represent hydrogen or (C₁-C₃)-alkyl groups, or taken together form a linear or branched (C₁-C₇)-alkylene group; R₄ represents halogen or (C₁-C₃)-(halo)-alkyl; m ranges from 0 to 4; R',R'', represent H, (C₁-C₃)-alkyl or halogen; n ranges from 0 to 3; y represents an optionally substituted -CH=CH₂, (C₃-C₆)-cycloalkyl, (C₆-C₁₀)-aryl, 5- or 6-membered heterocyclic or silyl group.
摘要:
An N-acylamino acid derivative of the formula: wherein each of R¹, R², R⁴ and R⁶ is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or a monocyclic or bicyclic heterocyclic group containing from 1 to 4 hetero atoms; each of R³ and R⁵ is hydrogen or lower alkyl; A is -CH(OH)-(CH₂) q R⁷ wherein R⁷ is hydrogen, lower alkyl, cycloalkyl, cyloalkylalkyl, aryl, aralkyl, a monocyclic or bicyclic heterocyclic group containing from 1 to 4 hetero atoms or -E-R¹⁰ wherein E is -S(O) i - wherein i is 0, 1 or 2, oxygen, -NR¹¹- wherein R¹¹ is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl, or wherein each of R¹² and R¹³ is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl, and R¹⁰ is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or a monocyclic or bicyclic heterocyclic group containing from 1 to 4 hetero atoms provided that when R¹⁰ is hydrogen, i is 0, and q is an integer of from 0 to 5; or -CH₂-CHR⁸-CO-R⁹ wherein R⁸ is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or a monocyclic or bicyclic heterocyclic group containig from 1 to 4 hetero atoms, and R⁹ is hydroxyl, -OX wherein X is alkyl, aryl, lower alkoxycarbonyloxyalkyl or 1-phthalidyl, or -N(Y¹)(Y²) wherein each of Y¹ and Y² is hydrogen, lower alkyl, aryl, aralkyl or cycloalkyl, or Y¹ and Y² form together with the adjacent nitrogen atom a 5- or 6-membered heterocyclic group which may contain a further hetero atom; m is 0, 1 or 2; and n is an integer of from 1 to 5, provided that when R¹ is hydrogen, m is 0; or a salt thereof, which is useful as hypotensive drugs.